---
title: "\"New Stocks\" ALEBUND-B dark market opening price reported at 23.26 yuan, up 2.9% from the listing price"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290935109.md"
description: "ALEBUND-B was listed on June 29th, with strong performance in the dark market. The Futu platform shows it opened 2.9% higher at HKD 23.26, then rose to HKD 39.82, up 76.2% from the issue price; the Phillip platform shows it opened 68.1% higher at HKD 38, currently reported at HKD 41.08, up 81.8% from the issue price. Both platforms recorded significant gains and considerable trading volume"
datetime: "2026-06-26T08:30:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290935109.md)
  - [en](https://longbridge.com/en/news/290935109.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290935109.md)
---

# "New Stocks" ALEBUND-B dark market opening price reported at 23.26 yuan, up 2.9% from the listing price

According to the Futu trading platform, on June 29th, ALEBUND-B (09637.HK) opened 2.9% higher in the dark market, reported at HKD 23.26, and is currently at HKD 39.82, up 76.2% or HKD 17.22 from the listing price, with a trading volume of 1.7189 million shares, involving HKD 69.3908 million.

According to the Phillip Securities trading platform, on June 29th, ALEBUND-B (09637.HK) opened 68.1% higher in the dark market, reported at HKD 38, and is currently at HKD 41.08, up 81.8% or HKD 18.48 from the listing price, with a trading volume of 1.04 million shares, involving HKD 43.30 million

### Related Stocks

- [09637.HK](https://longbridge.com/en/quote/09637.HK.md)
- [03588.HK](https://longbridge.com/en/quote/03588.HK.md)
- [FUTU.US](https://longbridge.com/en/quote/FUTU.US.md)

## Related News & Research

- [Biotech Firms Push Weight-Loss and AI Pipelines Amid Buyback Wave](https://longbridge.com/en/news/291029476.md)
- [Beijing Biostar Wins Shareholder Backing for Capital Mandates and Governance Changes at AGM](https://longbridge.com/en/news/290979536.md)
- [Beijing Biostar Pharmaceuticals files directors list with Hong Kong exchange](https://longbridge.com/en/news/290974298.md)
- [China Resources Pharmaceutical Raises RMB2 Billion in Third Tranche of 2026 PRC Bonds](https://longbridge.com/en/news/290965367.md)
- [Everest Medicines enters China commercialization collaboration with Hainan Herui for budesonide enteric capsules](https://longbridge.com/en/news/290642767.md)